Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Catalyst Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Catalyst Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT02970162
First received: November 16, 2016
Last updated: January 11, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)